10X GENOMICS, INC. (TXG): $152.38

-1.78 (-1.15%)

POWR Rating

Component Grades













Filter TXG News Items

TXG News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TXG News Highlights

  • TXG's 30 day story count now stands at 20.
  • Over the past 14 days, the trend for TXG's stories per day has been choppy and unclear. It has oscillated between 1 and 12.

Latest TXG News From Around the Web

Below are the latest news stories about 10x Genomics Inc that investors may wish to consider to help them evaluate TXG as an investment opportunity.

Genomics Market 2021 Research and Clinical Analysis -10X Genomics, Qiagen NV, Fluidigm Corporation, Johnson & Johnson Private Limited

The Global Genomics Market Research Report 2021-2030 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts

OpenPR | September 14, 2021

Why 10x Genomics Shares Are Trading Lower Today

10x Genomics (NASDAQ: TXG ) shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and announced a $180 price target. 10x Genomics'' stock is currently down 7.53% to a price of $156.27. Tuesday the stock has been traded

Business Insider Markets | September 14, 2021

Spatial Genomics and Transcriptomics Market worth $404 million by 2025 - Leading Key Players are 10X Genomics (US), NanoString Technologies Inc. (US), Illumina Inc. (US)

According to the new market research report "Spatial Genomics and Transcriptomics Market by Technique (Spatial Transcriptomics, Spatial Genomics), Product (Instruments, Consumables, Software), Application (Drug Discovery),End User (Academic Institute, Research Institutes, CROs)-Global Forecast to 2025", published by MarketsandMarkets, the Global Spatial

OpenPR | September 9, 2021

SoftBank Vision Fund’s Deep Nishar Is Discussing Leaving Firm

(Bloomberg) -- SoftBank Vision Fund’s sole senior managing partner, Deep Nishar, is discussing leaving the firm, according to people with knowledge of the matter.Nishar, who’s based in the San Francisco Bay Area, joined SoftBank in 2015, according to his LinkedIn profile. Previously a lecturer at Stanford University, he also served as a senior vice president of products and user experience at LinkedIn, and before that, worked at Google. Nishar also has a strong technical background, co-authoring

Yahoo | September 8, 2021

10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, September 13th, at 2:45 p.m. Eastern Time/11:45 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.10xgenomics.com/. A

Yahoo | August 31, 2021

Single-Cell Genome Sequencing Market Flourishing Globally with Best Rising Companies, Key Players - QIAGEN, Bio-Rad Laboratories, 10x Genomics.

New York, United States: In August, the Decisive Markets Insights have fabricated a report on the Single-Cell Genome Sequencing market that inculcates all the requirements of market facilitation worldwide. We are ready to provide you all the vital angles of

OpenPR | August 19, 2021

10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

PLEASANTON, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.

Intrado Digital Media | August 6, 2021

10x Genomics Reports Second Quarter 2021 Financial Results

Q2 2021 revenue growth of 170% over prior year and 9% over prior quarter PLEASANTON, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Revenue was $115.8 million for the second

10x Genomics | August 4, 2021

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2021

Worldwide: After Intense Patent Litigation Bio-Rad And 10x Genomics Settle Through Cross Licensing - Khurana and Khurana

Recently, in an announcement made by Pleasanton, California based 10x Genomics, Inc. ("10x") with US Stock exchanges and SEC (Securities and Exchange Commission), the company informed that it has

Mondaq | August 3, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.152 seconds.